Immunotherapy: Vaccine trials in melanoma -- time for reflection.
The disappointing results of the large, randomized, controlled trials showing no benefit of vaccines in patients with advanced and metastatic melanoma call for a reassessment of the development of therapeutic vaccines and the importance of better immune monitoring methodology, such as adoptive T-cell therapy with lymphodepletion.
Eggermont
Alexander M M
AM
Department of Surgical Oncology, Daniel den Hoed Cancer Center, Erasmus University MC, Rotterdam, The Netherlands. a.eggermont@erasmusmc.nl
D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000627:therapeutic use; D008545:Melanoma / Q000473:pathology* / Q000556:secondary / Q000628:therapy*; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D016032:Randomized Controlled Trials as Topic; D012878:Skin Neoplasms / Q000473:pathology* / Q000628:therapy*
D019496:Cancer Vaccines; D007376:Interleukin-2